Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

Blood (2024) 144 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2024-202335

Published: 2024

Journal Articles

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents

Luis A. Carvajal, Michael McKeown, Tressa Hood, Pavan Kumar, Douglas C. Saffran, Jorge DiMartino

Blood (2022) 140 (Supplement 1): 5932–5933.

https://doi.org/10.1182/blood-2022-159087

Published: 2022

Journal Articles

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Luis A. Carvajal, Tressa Hood, Yana Bevan, Richard Dillon, Nicola Potter, Ian Thomas, Sean Johnson, Jad Othman, Amanda Gilkes, Nigel H. Russell, Adam Sikorski, Pete Ellis, Giovanni Marsico, Greg Jones, Crystal MacKenzie, Zung To, Jorge DiMartino, Pavan Kumar

Blood (2022) 140 (Supplement 1): 3377–3378.

https://doi.org/10.1182/blood-2022-159154

Published: 2022

Journal Articles

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

John C. Byrd, Jorge E. Cortes, Mark D. Minden, Thomas Oellerich, Eytan M. Stein, Jenna Elder, Pavan Kumar, Gordon Bray, Jorge DiMartino, Wendy Stock

Blood (2021) 138 (Supplement 1): 1282.

https://doi.org/10.1182/blood-2021-145773

Published: 2021

Journal Articles

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

Melinda A. L. Day, Philipp Sergeev, Caroline A. Heckman, Anna Schinzel, Nikolaus D. Obholzer, Charles Y. Lin, Pavan Kumar, Jorge DiMartino, Douglas C. Saffran

Blood (2021) 138 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2021-146180

Published: 2021

Journal Articles

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

Blood (2020) 136 (13): 1520–1534.

https://doi.org/10.1182/blood.2019002655

Published: 2020

Includes: Supplemental data

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Chandrika Gowda, MBBS, Chunhua Song, MD, Yali Ding, PhD, Pavan kumar Dhanyamraju, PhD, Soumya Iyer, PhD, Jonathon Payne, Yevgeniya Bamme, MD, Arati Sharma, PhD, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2634.

https://doi.org/10.1182/blood-2019-131790

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Chandrika Gowda, MBBS, Chunhua Song, MD, Sadie Steffens, PhD, Yali Ding, PhD, Bo Zhang, Feng Yue, PhD, Soumya Iyer, PhD, Pavan kumar Dhanyamraju, PhD, Jonathon Payne, Morgann Reed, BS, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2522.

https://doi.org/10.1182/blood-2019-131200

Published: 2019

Journal Articles

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Ningying Wu, PhD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, John F DiPersio, MD PhD, Camille N. Abboud, MD

Blood (2017) 130 (Supplement 1): 3204.

https://doi.org/10.1182/blood.V130.Suppl_1.3204.3204

Published: 2017

Journal Articles

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

Pavan Kumar Bhamidipati, MBBS, MD, Armin Ghobadi, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Peter Westervelt, MDPhD, Geoffrey L. Uy, MD, Camille N. Abboud, MD, Mark A. Schroeder, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4566.

https://doi.org/10.1182/blood.V130.Suppl_1.4566.4566

Published: 2017

Journal Articles

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Pavan Kumar Bhamidipati, MBBS, MD, Han Se-Young, MD, Shivaprasad Manjappa, MD, Feng Gao, PhD, Mark A. Schroeder, MD, Ravi Vij, MDMBA, Amanda F. Cashen, MD, Camille N. Abboud, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 4567.

https://doi.org/10.1182/blood.V130.Suppl_1.4567.4567

Published: 2017

Journal Articles

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Shivaprasad Manjappa, MD, Mark A. Fiala, BS, Pavan Kumar Bhamidipati, MBBS, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MDMBA, Tanya M. Wildes, MDMSCI

Blood (2017) 130 (Supplement 1): 1860.

https://doi.org/10.1182/blood.V130.Suppl_1.1860.1860

Published: 2017

Journal Articles

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

Se young Han, MD, Rizwan Romee, MD, Michael Slade, BA, Pavan Kumar Bhamidipati, MBBS, MD, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, Yu Tao, PhD

Blood (2016) 128 (22): 3477.

https://doi.org/10.1182/blood.V128.22.3477.3477

Published: 2016

Journal Articles

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

Dhruv Bansal, MD, Pavan Kumar Bhamidipati, MBBS, MD, Natasha Catherine Edwin, MD, Michael Slade, BA, John F DiPersio, MD PhD, Peter Westervelt, MD PhD, Ravi Vij, MD, Mark A. Schroeder, MD, Geoffrey L. Uy, MD, Jingxia Liu, Rizwan Romee, MD

Blood (2016) 128 (22): 4696.

https://doi.org/10.1182/blood.V128.22.4696.4696

Published: 2016

Journal Articles

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Vincent Ribrag, Jean-Charles Soria, Professor, Jean-Marie Michot, Anna Schmitt, MD, Sophie Postel-Vinay, MD, Fontanet Bijou, MD, Blythe Thomson, MD, Heike Keilhack, PhD, Stephen J. Blakemore, PhD, Larisa Reyderman, PhD, Pavan Kumar, PhD, Greg Fine, MS, Alice McDonald, Peter T Ho, PhD MD, Antoine Italiano, MD

Blood (2015) 126 (23): 473.

https://doi.org/10.1182/blood.V126.23.473.473

Published: 2015

Journal Articles

Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation

Se young Han, MD, Pavan Kumar Bhamidipati, MBBS,MD, Khoan Vu, MD, John F Dipersio, MD PhD, Feng Gao, PhD, Iskra Pusic, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MD, Mark A. Schroeder, MD, Camille N. Abboud, MD FACP, Keith Stockerl-Goldstein, MD, Amanda F. Cashen, MD, Todd A Fehniger, MD PhD, Rizwan Romee, MD

Blood (2015) 126 (23): 3144.

https://doi.org/10.1182/blood.V126.23.3144.3144

Published: 2015

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Ramzi Abboud, MD, Jesse Keller, MD, Michael Slade, BA, Michael P. Rettig, PhD, Stephanie Meier, John F. DiPersio, MD PhD, Todd A Fehniger, MD PhD, Kathryn Trinkaus, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, Ravi Vij, MD, Camille N. Abboud, MD FACP, Khoan Vu, MD, Pavan Kumar Bhamidipati, MBBS,MD, Rizwan Romee, MD

Blood (2015) 126 (23): 3106.

https://doi.org/10.1182/blood.V126.23.3106.3106

Published: 2015

Journal Articles

Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells

Blood (2015) 126 (23): 1643.

https://doi.org/10.1182/blood.V126.23.1643.1643

Published: 2015

Journal Articles

Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation

Blood (2014) 124 (21): 4615.

https://doi.org/10.1182/blood.V124.21.4615.4615

Published: 2014

Journal Articles

Haploidentical Peripheral Blood Stem Cell Transplantation Using Non-Myeloablative Conditioning With Post-Transplant Cyclophosphamide Regimen Is Safe and Is Associated With Very Encouraging Post-Transplant Outcomes

Pavan Kumar Bhamidipati, MD, John F. DiPersio, MD, PhD, Keith Stokerl-Goldstein, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD, PhD, Feng Gao, PhD, Ravi Vij, MD, Mark A. Schroeder, MD, Camille N. Abboud, MD, Iskra Pusic, MD, Shivaprasad Manjappa, MD, Rizwan Romee, MD

Blood (2013) 122 (21): 4532.

https://doi.org/10.1182/blood.V122.21.4532.4532

Published: 2013

NARROW

Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile

SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Entospletinib in Combination with Intensive Induction and Consolidation Chemotherapy in Adults with Newly Diagnosed N ucleophosmin 1- mutated Acute Myeloid Leukemia

Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds

IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity in high-risk B-cell acute lymphoblastic leukemia

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape

Outcomes of Patients with Baseline Marrow Fibrosis at Allogeneic Hematopoietic Cell Transplantation

Clinical Characteristics of Isolated CNS Relapse after Allogeneic Transplantation for AML — Poor Outcomes Despite Longer Time to Relapse

FLT3 Positivity Is a Predictor of Early Relapse Post-Transplantation — Allo-HCT Is an Ineffective Salvage Strategy in Active AML

Statin Use Is Associated with Decreased Mortality in Multiple Myeloma— a SEER Medicare Study

Reduced Intensity Hematopoietic Cell Transplantation in Active Disease AML Is Associated with Leukemia Free Survival and Relapse Comparable to Myeloablative Conditioning

Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients

Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation

T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy

Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells

Cancer-Associated Mutations in SF3B1 Exhibit Neomorphic Splicing Activity and Block Erythroid Differentiation

Haploidentical Peripheral Blood Stem Cell Transplantation Using Non-Myeloablative Conditioning With Post-Transplant Cyclophosphamide Regimen Is Safe and Is Associated With Very Encouraging Post-Transplant Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only